+

Visit Booth #1232

Leading the Innovation in Mitral and Tricuspid Therapies & Advancing Clinical Evidence at TCT 2025

Get TCT Updates

Join Abbott at TCT 2025 to learn about advancements in mitral and tricuspid valve therapies. Visit us at booth #1232 to get hands-on experience on our latest mitral and tricuspid technologies.

Attend our featured symposium, A Firm Grasp with G5: Where Control Meets Efficiency.
 

Featured Experts:

Dr. Christian Spies
Co-moderator

Dr. Robert Cubeddu
 

Dr. Matthew Sherwood
Co-moderator

Dr. Sudeshna Banerjee
 

Dr. Lucy Safi
 

Dr. Daniel Hermann
 

Driving Better Outcomes with MitraClip, TriClip, Tendyne, and Cephea* — TCT 2025 Presentations

Saturday, October 25, 2025

PODIUM PRESENTATION
10:40 AM

Impact of Primary Jet Location on Clinical Outcomes: Results from the EXPANDed Studies 

Presenter: Dr. Jason Rogers

  Station 2, Hall D, Exhibition Level, Moscone South

Add to calendar

VALVE COORDINATOR DINNER
5:30 – 8:30 PM

Managing the Expanding Structural Heart Priorities for Valve Coordinators

Join us for an evening of collaborative discussion around the growing priorities and how to prepare for the evolving structural heart program needs. Dive into next-generation technologies for improving quality outcomes and planning for lifetime management.

Morton's The Steakhouse, San Francisco

Register

Sunday, October 26, 2025

SCIENTIFIC SYMPOSIUM
12:15 – 1:30 PM

A Firm Grasp with G5: Where Control Meets Efficiency

Moderators: Dr. Christian Spies, Dr. Matthew Sherwood 
Speakers: Dr. Lucy Safi, Dr. Robert Cubeddu, Dr. Sudeshna Banerjee, Dr. Danny Hermann

Presentation Theater 1, Hall D, Exhibition Level, Moscone South

Add to calendar

PODIUM PRESENTATION
3:12 PM

Lessons Learned from 800+ Patients Treated with Tricuspid TEER: Update from the TRILUMINATE™ Pivotal Trial

Presenter: Dr. Jonathan Schwartz

Main Arena, Hall A, Exhibition Level, Moscone South

Add to calendar

Monday, October 27, 2025

PODIUM PRESENTATION
9:50 AM

Cephea™* Mitral Valve System for Symptomatic Mitral Valve Disease: 1-Year Outcomes of the Early Feasibility Study 

Presenter: Dr. Torsten Vahl

  Innovation Theater, Hall E, Exhibition Level, Moscone North

Add to calendar

PODIUM PRESENTATION
11:44 AM

Tendyne™ Transcatheter Mitral Valve System in Patients with Severe Mitral Annular Calcification: One-year Outcomes from the SUMMIT Severe MAC Cohort 

Presenter: Dr. Paul Sorajja

  Main Arena, Hall A, Exhibition Level, Moscone South

Add to calendar

Explore Our Mitral and Tricuspid Solutions

TEER

MitraClip 

The first and only U.S.-approved TEER therapy for both primary and secondary MR, supported by 20+ years of evidence and over 200,000 patients treated worldwide. Its proven outcomes and broad adoption make it the most widely used transcatheter mitral valve repair therapy worldwide.1

Learn more about MitraClip

TriClip 

TriClip is the only TEER therapy intentionally designed for the tricuspid valve to improve quality of life and functional status in patients with symptomatic severe tricuspid regurgitation at intermediate or greater risk for surgery.2 It delivers precise delivery, stable navigation, and significant TR reduction with an exceptional safety profile.3-7

Learn more about TriClip

TMVR

Tendyne

Tendyne is the world’s first transcatheter mitral valve replacement system designed to treat symptomatic mitral valve dysfunction associated with severe mitral annular calcification (MAC) in patients who are deemed unsuitable for mitral valve surgery or transcatheter edge-to-edge repair; offering sustained MR reduction and improved quality of life.

Cephea

Cephea* is an investigational mitral valve replacement system being developed to provide a less-invasive option delivered via a transfemoral approach, aiming to expand treatment possibilities for patients with mitral valve disease.

Learn more about Cephea Early Feasibility Study

*Currently in development at Abbott. Not available for sale. Subject to change.

Don’t Miss a Beat – Sign up to receive the recorded symposia and the latest data post-TCT.

MAT-2511653 v2.0 | Item approved for U.S. use only.

References

*Currently in development at Abbott. Not available for sale. Subject to change.

  1. Data on file at Abbott.
  2. TriClip G5 System IFU.
  3. Test(s) performed by and data on file at Abbott. (RPT2118537)
  4. Test(s) performed by and data on file at Abbott. (RPT2105461-R)
  5. Estevez-Loureiro R. Real-world Outcomes for Tricuspid Edge-to-Edge Repair: Initial 2-year Outcomes from the bRIGHT Trial. Presented at PCR London Valves on November 19-21, 2023; London, UK.
  6. Adams D, Sorajja P, et al. TRILUMINATE Pivotal: Outcomes of All Randomized and Single-arm Subjects with Transcatheter Tricuspid Valve Edge-to-Edge Repair for Tricuspid Regurgitation. Presented at TCT on October 24, 2023; San Francisco, CA; USA.
  7. Sorajja P, Whisenant B, Hamid N, et al. Transcatheter repair for patients with tricuspid regurgitation. NEJM. March 4, 2023. doi: 10.1056/NEJMoa2300525.
Important Safety Information
  • MitraClip
  • TriClip
  • Tendyne

  • Rx Only

    MITRACLIP™ CLIP DELIVERY SYSTEM

    INDICATIONS FOR USE

    The MitraClip™ G5 System is indicated for the percutaneous reduction of significant symptomatic mitral regurgitation (MR ≥ 3+) due to primary abnormality of the mitral apparatus [degenerative MR] in patients who have been determined to be at prohibitive risk for mitral valve surgery by a heart team, which includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease, and in whom existing comorbidities would not preclude the expected benefit from reduction of the mitral regurgitation.

    The MitraClip™ G5 System, when used with maximally tolerated guideline-directed medical therapy (GDMT), is indicated for the treatment of symptomatic, moderate-to-severe or severe secondary (or functional) mitral regurgitation (MR; MR ≥ Grade III per American Society of Echocardiography criteria) in patients with a left ventricular ejection fraction (LVEF) ≥ 20% and ≤ 50%, and a left ventricular end systolic dimension (LVESD) ≤ 70 mm whose symptoms and MR severity persist despite maximally tolerated GDMT as determined by a multidisciplinary heart team experienced in the evaluation and treatment of heart failure and mitral valve disease.

    CONTRAINDICATIONS

    The MitraClip™ G5 System is contraindicated for use in patients with the following conditions:

    • Intolerance, including allergy or untreatable hypersensitivity to, procedural anticoagulation
    • Untreatable hypersensitivity to Implant components (nickel-titanium alloy, cobalt-chromium alloy)
    • Active endocarditis or other active infection of the mitral valve

    POTENTIAL COMPLICATIONS AND ADVERSE EVENTS

    The following events have been identified as possible complications of the MitraClip™ G5 procedure: Allergic reactions or hypersensitivity to latex, contrast agent, anaesthesia, device materials, and drug reactions to anticoagulation or antiplatelet drugs; Additional treatment/surgery from device-related complications; Atrial septal defect; Bleeding; Blood disorders (including coagulopathy, hemolysis, and Heparin Induced Thrombocytopenia (HIT)); Cardiac arrhythmias (including conduction disorders, atrial arrhythmias, ventricular arrhythmias); Cardiac ischemic conditions (including myocardial infarction, myocardial ischemia, unstable angina, and stable angina); Cardiac perforation; Cardiac tamponade; Chest pain; Death; Dyspnea; Edema; Embolization (device or components of the device); Endocarditis; Fever or hyperthermia; Fluoroscopy and Transesophageal echocardiogram (TEE)-related complications: Skin injury or tissue changes due to exposure to ionizing radiation, Esophageal irritation, Esophageal perforation, Gastrointestinal bleeding; Hypotension / hypertension; Infection including: Septicemia; Mitral valve complications, which may complicate or prevent later surgical repair, including: Chordal entanglement / rupture, Single leaflet device attachment (SLDA), Dislodgement of previously implanted devices, Tissue damage, Mitral valve stenosis, Worsening, persistent or residual regurgitation; Nausea or vomiting; Pain; Pericardial effusion; Stroke / cerebrovascular accident (CVA) and transient ischemic attack (TIA); System organ failure: Cardio-respiratory arrest, Worsening heart failure, Pulmonary congestion, Respiratory dysfunction or failure or atelectasis, Renal insufficiency or failure, Shock (including cardiogenic and anaphylactic); Thrombosis; Vascular access complications which may require additional intervention, including: Wound dehiscence, Bleeding of the access site, Arteriovenous fistula, Pseudoaneurysm, Aneurysm, Dissection, Perforation (rupture), Vascular occlusion, Embolism (air, thrombus), Peripheral nerve injury; Venous thrombosis (including deep vein thrombosis) and thromboembolism (including pulmonary embolism).

  • Rx Only

    TRICLIP™ G5 SYSTEM

    INDICATION FOR USE

    The TriClip™ G5 System is indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy, who are at intermediate or greater risk for surgery and in whom transcatheter edge-to-edge valve repair is clinically appropriate and is expected to reduce tricuspid regurgitation severity to moderate or less, as determined by a multidisciplinary heart team.

    CONTRAINDICATIONS

    The TriClip™ G5 System is contraindicated for use in patients with the following conditions: Intolerance, including allergy or untreatable hypersensitivity, to procedural anticoagulation; Untreatable hypersensitivity to Implant components (nickel-titanium alloy, cobalt-chromium alloy); Active endocarditis or other active infection of the tricuspid valve.

    POTENTIAL ADVERSE EVENTS

    The following events have been identified as possible complications of the TriClip™ G5 Procedure. Allergic reactions or hypersensitivity to latex, contrast agent, anaesthesia, device materials and drug reactions to anticoagulation, or antiplatelet drugs; Additional treatment / surgery from device-related complications; Bleeding; Blood disorders (including coagulopathy, hemolysis, and Heparin Induced Thrombocytopenia (HIT)); Cardiac arrhythmias (including conduction disorders, atrial arrhythmias, ventricular arrhythmias); Cardiac ischemic conditions (including myocardial infarction, myocardial ischemia, unstable angina, and stable angina); Cardiac perforation; Cardiac tamponade; Chest pain; Death; Dyspnea; Edema; Embolization (device or components of the device); Endocarditis; Fever or hyperthermia; Fluoroscopy and Transesophageal echocardiogram (TEE) -related complications: Skin injury or tissue changes due to exposure to ionizing radiation, Esophageal irritation, Esophageal perforation, Gastrointestinal bleeding; Hypotension / hypertension; Infection including: Septicemia; Nausea or vomiting; Pain; Pericardial effusion; Stroke / cerebrovascular accident (CVA) and transient ischemic attack (TIA); System organ failure: Cardio-respiratory arrest, Worsening heart failure, Pulmonary congestion, Respiratory dysfunction or failure or atelectasis, Renal insufficiency or failure, Shock (including cardiogenic and anaphylactic); Thrombosis; Tricuspid valve complications, which may complicate or prevent later surgical repair, including: Chordal entanglement / rupture, Single leaflet device attachment (SLDA), Dislodgement of previously implanted devices, Tissue damage, Tricuspid valve stenosis, Worsening, persistent or residual regurgitation; Vascular access complications which may require additional intervention, including: Wound dehiscence, Bleeding of the access site, Arteriovenous fistula, pseudoaneurysm, aneurysm, dissection, perforation (rupture), vascular occlusion, Embolism (air, thrombus), Peripheral nerve injury; Venous thrombosis (including deep vein thrombosis) and thromboembolism (including pulmonary embolism).

  • Rx Only

    TENDYNE™ TRANSCATHETER MITRAL VALVE SYSTEM

    INDICATIONS FOR USE

    The Tendyne™ Transcatheter Mitral Valve System is indicated for the treatment of symptomatic severe mitral valve dysfunction (moderate-to-severe or severe mitral regurgitation (MR), severe mitral stenosis (MS), or moderate MR with moderate or greater MS) associated with severe mitral annular calcification (MAC) in patients who are deemed unsuitable for mitral valve surgery or transcatheter edge-to-edge repair by a multidisciplinary heart team.

    CONTRAINDICATIONS

    The Tendyne™ Transcatheter Mitral Valve System is contraindicated in patients with:

    • anticoagulation/antiplatelet intolerance;
    • sepsis or active endocarditis;
    • evidence of left ventricular or left atrial thrombus at risk of embolization;
    • a thin or fragile apex rendering the subject unsuitable for a transapical procedure; or
    • untreatable hypersensitivity to nickel or titanium

    Patients not deemed a candidate by the local heart team based on clinical or anatomical factors should not have the Tendyne™ Transcatheter Mitral Valve procedure.

    POTENTIAL COMPLICATIONS AND ADVERSE EVENTS

    Adverse events potentially associated with use of the Tendyne™ Transcatheter Mitral Valve System may include, but are not limited to, the following:

    Death, Adverse foreign body response, Adverse reaction to anesthesia, Allergic reaction, Anemia, Annular dissection, Aortic insufficiency, Atrial or ventricular injury, Atrial Septal Defect (resulting from transseptal mitral valvuloplasty, if performed), Bioprosthetic valve dysfunction, Bleeding complications, Blood loss which may require transfusion, Cardiac arrest, Cardiac perforation, Conduction defect with or without need for pacemaker, Cardiac arrhythmia, atrial or ventricular, Damage to cardiac tissue and/or structures, Decreased LV function and/or cardiac output, Device embolism, Device erosion, migration or malposition, Device thrombosis, Embolism (air, blood clot, calcium, tissue, etc.), Endocarditis, Esophageal irritation, stricture, or perforation, Fever, Foreign body response, Heart Failure, new or worsening, Hematoma, Hemolysis, Hypotension, Infection / Sepsis, Leaflet, chordal, papillary or ventricular rupture (resulting from mitral valvuloplasty, if performed), Liver failure, Mitral valve injury, Mitral valve prolapse / stenosis, Myocardial infarction, Obstruction, Pain, Pleural effusion, Pulmonary embolism, Pulmonary hypertension, Paravalvular leak, Pericardial effusion / tamponade, Renal insufficiency or failure, Respiratory difficulty, insufficiency or failure, Stroke or transient ischemic attack, Tear or damage to device, Vascular and access-related complications, Worsening of mitral regurgitation.

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

U.S. VISITOR INTERNATIONAL VISITOR

YOU ARE ABOUT TO LEAVE
www.structural­heart.abbott

You are now leaving www.structuralheart.abbott. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

OkCancel
+